Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.96 USD | +1.02% |
|
+7.45% | +0.71% |
03:31pm | Celldex Therapeutics Launches Phase 3 Trials for Barzolvolimab in Patients With Chronic Skin Inflammation | MT |
06-18 | Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.71% | 2.61B | |
+24.18% | 46.56B | |
+45.38% | 41.67B | |
-0.31% | 41.16B | |
+33.55% | 32.4B | |
+20.81% | 28.18B | |
-6.35% | 28.1B | |
+49.48% | 14.52B | |
+47.50% | 13.74B | |
+2.14% | 12.17B |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- Insider Sell: Celldex Therapeutics